Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

In this week's podcast edition of Scrip's Five Must-Know Things: US industry warns over pricing; a setback for another gene therapy; a Phase II disappointment for Novartis; Actemra shortages cause CAR-T worries; and Sweden's Sobi set to go private. 

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 10 September 2021, including: US industry warns over pricing; a setback for another gene therapy; a Phase II blow for Novartis’s transplant drug; Actemra shortages cause CAR-T challenges; and Sweden’s Sobi set to go private.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Pharma On Its Back Foot As US Drug Price Reform Advances" - Scrip, 8 Sep, 2021.)

(Also see "Novartis's Big Hopes For Transplant Drug Blown Apart" - Scrip, 3 Sep, 2021.)

(Also see "COVID-19-Induced Actemra Shortage Causes Headaches For CAR-T Centers" - Scrip, 6 Sep, 2021.)

(Also see "Sobi To Go Private In $8.1bn Buyout That Appreciates Growth Strategy" - Scrip, 2 Sep, 2021.)

 

Related Content

Topics

UsernamePublicRestriction

Register

SC145055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel